Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Northera
Droxidopa, also known as L-threo-dihydroxyphenylserine (L-threo-DOPS), is a synthetic precursor of norepinephrine used to treat neurogenic orthostatic hypotension (nOH), a condition characterized by a drop in blood pressure upon standing. It belongs to the class of sympathomimetic agents and works by increasing levels of norepinephrine, a neurotransmitter responsible for maintaining blood pressure. Droxidopa is converted to norepinephrine in the body, helping to constrict blood vessels and increase blood pressure, thereby alleviating symptoms of nOH such as dizziness, lightheadedness, and fainting.
For the treatment of neurogenic orthostatic hypotension (nOH).
Outcome:
Hypertensive crisis
Mechanism:
Increased norepinephrine levels
Outcome:
Reduced antihypertensive effect
Mechanism:
Opposing actions on blood pressure
Outcome:
Slightly decreased droxidopa absorption
Mechanism:
Changes in stomach pH
Most likely new formulation: Extended-release droxidopa (Year 2026, 60% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of droxidopa maintaining its current FDA approval status for nOH over the next 5 years.
Sympathomimetic Agent, Norepinephrine Precursor
Amino Acid Derivative